Assessment of Lysosome-Associated Membrane Protein (LAMP5) in Newly Diagnosed Multiple Myeloma Patients and Correlation to Clinical Outcome

Introduction: Lysosome-associated membrane protein 5(LAMP5) is one of the glycosylated proteins which are implicated in several different features of cell biology and can impact cellular processes for instance phagocytosis, autophagy, lipid transference, and aging.Interestingly, it has a significant role in cancer progression, metastatic spread and aggressiveness.It has been reported to be significantly expressed in many hematopoietic malignancies as leukemias and Multiple Myeloma (MM).Objectives: This study used enzyme-linked immunosorbent assay (ELISA) to measure the level of LAMP5 in newly diagnosed MM patients, and the level was correlated to the clinical outcome of the patient.Methods: A prospective study was done on 64 people, including 32 newly diagnosed MM patients and 32 age-and gender-matched healthy controls.ELISA was used to assess the levels of LAMP5 in serum samples.Clinical data and LAMP5 expression correlations were assessed.Results: MM patients' LAMP5 levels were found to be statistically significantly higher than those of healthy controls (P<0.0001),However, LAMP5 does not correlate with clinical outcomes, laboratory results, or patient clinical data.Conclusion: This report emphasizes that LAMP5 expression in newly diagnosed multiple myeloma patients was highly significant by ELISA and its influence on patient's prognosis still unclear as there was no significant correlation with other clinical data, which indicates more research on large scale of patients to determine its significance of its expression on prognosis.